earnings
confidence high
sentiment positive
materiality 0.85
Immuneering: FY2025 net loss $56M, cash $217M, 64% OS at 12 months in pancreatic cancer
Immuneering Corp
- Net loss for FY2025 was $56.0M ($1.27/share), down from $61.0M ($2.04/share) in 2024.
- Cash and marketable securities $217.0M as of Dec 31, 2025, with anticipated runway into 2029.
- Phase 2a pancreatic cancer data: 64% OS at 12 months for atebimetinib + mGnP, above standard of care 35%.
- Pivotal Phase 3 MAPKeeper 301 on track to dose first patient mid-2026; FDA and EMA alignment secured.
- Plan to dose first patient in Phase 2 trial of atebimetinib + Libtayo in RAS-mutant NSCLC in 2H 2026.